Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125. PMID: 16611061
Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125. PMID: 21541316
Computational Modulation of the V3 Region of Glycoprotein gp125 of HIV-2. PMID: 33669351
Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination. PMID: 15920286
Identification of B-cell antigenic sites on HIV-2 gp125. PMID: 1370692
Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins. PMID: 7888225
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins. PMID: 16455923
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. PMID: 8896498
Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2. PMID: 10333245
Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2. PMID: 8120399
Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification. PMID: 9606017
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. PMID: 20463072
Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125. PMID: 9079375
Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies. PMID: 15566829
Characterization of human immunodeficiency virus type 2 envelope glycoproteins: dimerization of the glycoprotein precursor during processing. PMID: 2911118
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. PMID: 15194778
Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers. PMID: 2296088
HIV-2 A-subtype gp125c₂-v₃-c₃ mutations and their association with CCR5 and CXCR4 tropism. PMID: 21814863
Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1. PMID: 2229392
HIV-2 neutralization by intact V3-specific Fab fragments. PMID: 18706111
A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2. PMID: 21232554
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. PMID: 18981765
Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity. PMID: 9566765
Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2. PMID: 10854165
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. PMID: 12706073
Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2. PMID: 1710645
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. PMID: 20844029
The role of eukaryotic subtilisin-like endoproteases for the activation of human immunodeficiency virus glycoproteins in natural host cells. PMID: 8995623
Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. PMID: 11413371
Cell-mediated immunity to low doses of SIVsm in cynomolgus macaques did not confer protection against mucosal rechallenge. PMID: 10930685
Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. PMID: 10466795
Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8. PMID: 19574645
In vivo genetic variability of the human immunodeficiency virus type 2 V3 region. PMID: 1602560
Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. PMID: 2068087
Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals. PMID: 7504937
Vaccine protection against HIV-2 infection in cynomolgus monkeys. PMID: 2064826
Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmission. PMID: 9525673
Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. PMID: 8176640
Crystal structure of the HIV-2 neutralizing Fab fragment 7C8 with high specificity to the V3 region of gp125., PMID:21541316
A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and -2., PMID:21232554
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy., PMID:20844029
Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8., PMID:19574645
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression., PMID:18981765
HIV-2 neutralization by intact V3-specific Fab fragments., PMID:18706111
Deletion of the V1/V2 region does not increase the accessibility of the V3 region of recombinant gp125., PMID:16611061
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins., PMID:16455923
Cloning, expression, and purification of HIV-2 gp125: A target for HIV vaccination., PMID:15920286
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals., PMID:15194778
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection., PMID:12706073
Fine characterization of a V3-region neutralizing epitope in human immunodeficiency virus type 2., PMID:10854165
Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display., PMID:10466795
Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2., PMID:10333245
Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification., PMID:9606017
Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity., PMID:9566765
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys., PMID:8896498
Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies., PMID:15566829
Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins., PMID:7888225
Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine., PMID:8176640
Two neutralizing domains in the V3 region in the envelope glycoprotein gp125 of HIV type 2., PMID:8120399
Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals., PMID:7504937
Identification of B-cell antigenic sites on HIV-2 gp125., PMID:1370692
Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity., PMID:2068087
Characterization of human antibody-binding sites on the external envelope of human immunodeficiency virus type 2., PMID:1710645
Vaccine protection against HIV-2 infection in cynomolgus monkeys., PMID:2064826
Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1., PMID:2229392
Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers., PMID:2296088
For research use only. Not for human or drug use.
